The CCS is committed to preserving the scientific integrity of its Guidelines, Clinical Practice Updates and Position Statements through transparency and management of disclosures (industry, academic, other). Panel members must disclose all relationships with industry regardless of relevance to the statement topic. When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit www.ccs.ca.

			on the CCS Guideline Development process, p		ant of this statement
Member	Affilations with commercial organizations within the previous two years that may have a direct or indirect connections to the content of this statement Consulting Fees/				
Weinser		Honoraria	Clinical Trials	Other Financial Benefits	Relevance to Statement
			Primary Panel		
Co-Cl	hairs	T			T
Christopher B.	Fordyce	Amgen, Bayer, Boehringer Ingelheim, Novo Nordisk, Novartis, Pendopharm, New Amsterdam	Steering Committee: HeartFlow	Research Grant: Bayer, BMS-Pfizer, Canadian Cardiovascular Society	No direct relationship
Andreas H.	Kramer	None	None	None	None
Panel me	embers				
Craig	Ainsworth	None	None	None	None
Emilie	Belley-Côté	None	Bayer, Roche and BMS-Pfizer	None	No direct relationship
Jim	Christenson	None	Brain Canada, CanROC Cardiac Arrest Registry, FRONTIER trial of a neuroprotectant in hot strokes, Heart and Stroke Canada, NoNO Inc., Stryker, Zoll	None	No direct relationship
Laura	Dragoi	None	None	None	None
Gary	Hunter	None	None	None	None
Colin	Josephson	Eisai Inc., UCB Canada Inc.	None	None	No direct relationship
Julie	Kromm	None	None	None	None
Demetrios	Kutsogiannis	None	None	None	None
Michel	LeMay	None	None	None	None
Carmen	Lopez	None	None	None	None
Chris	Overgaard	None	None	None	None
Martin	Savard	Eisai Inc., UCB Canada Inc.	None	None	No direct relationship
Damon	Scales	None	CIHR, Heart and Stroke Foundation of Canada	None	None
Greg	Schnell	None	None	None	None
Mypinder	Sekhorn	None	None	None	None
Sean	van Diepen	None	None	None	None
Graham	Wong	Amgen, Bayer, Novartis	None	None	No direct relationship
		I	Secondary Panel		T
Tadeu A.	Fantaneanu	UCB Canada, Eisai	None	None	No direct relationship
Christopher	Granger	Abbvie, Abiomed, Alnylam Pharmaceuticals, Anthos, Bayer Corporation, Boston Scientific Corporation, Bristol Myers Squibb, Cadrenal, Cardionomics, Janssen Pharmaceutical, Medscape, LLC, Medtronic, Inc., Merck, Novo Nordisk, Novartis Pharmaceutical Company, Pfizer, Philips, NephroSynergy	United States National Institutes of Health, Celecor, Boehringer Ingelheim	Equity in Tenac.io	Cluster randomized trial to improve surviva from out of hospital cardiac arrest in North Carolina
Adriana	Luk	None	None	None	None
Rebecca	Mathew	None	None	None	None
Victoria A.	McCredie	None	None	None	None
Laurel	Murphy	None	None	None	None

